A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
Phase of Trial: Phase I/II
Latest Information Update: 30 Mar 2018
At a glance
- Drugs NBTXR 3 (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors PharmaEngine
- 30 Mar 2018 According to a company media release, company will present an interim results from this study with high risk elderly patients in 2018.
- 30 Mar 2018 According to a company media release, Nanobiotix filed a protocol amendment of this study to expand more patients to confirm the efficacy of NBTXR3. Company is planning to open 12-15 additional clinical trial sites in Europe and to expand this study to the U.S. at a later stage.
- 09 Nov 2017 According to a company media release, Nanobiotix filed a protocol amendment of this study to include 44 additional patients. Nanobiotix is also opening 12-15 additional sites in Europe to expand the development of this indication.